Press Releases

Date Title
Toggle Summary vTv Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 19, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that company management will present a corporate overview at the Piper Jaffray 30 th Annual Healthcare Conference on Tuesday, Nov. 27, 2018 at 2:10 p.m. ET in New York City .
View HTML
Toggle Summary vTv Therapeutics Announces Third Quarter 2018 Results and Update
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 8, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT) today reported financial results for the third quarter that ended September 30, 2018 , and provided an update on recent achievements and upcoming events. “We continue to believe in the therapeutic potential of
View HTML
Toggle Summary vTv Therapeutics Announces Transfer of Listing to The Nasdaq Capital Market
HIGH POINT, N.C. --(BUSINESS WIRE)--Oct. 29, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease (AD) and diabetes, today announced that The NASDAQ Stock Market LLC
View HTML
Toggle Summary vTv Therapeutics Presents Positive Data on the Effect of Azeliragon in Patients with Alzheimer’s and Diabetes at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Subgroup Analysis Indicates Potential Benefit of Treatment with Azeliragon for Patients with Type 2 Diabetes and Alzheimer’s Disease Nearly 40 percent of Medicare Beneficiaries with Dementia Also Suffer from Diabetes, a Large Population to Potentially Benefit HIGH POINT, N.C.
View HTML
Toggle Summary vTv Therapeutics to Deliver Two Presentations at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
Results of the Azeliragon Phase 3 STEADFAST Trial to be Presented during Oral Session Subgroup Data Discussing the Effect of Azeliragon in Patients with Dementia and Diabetes to be Presented during Poster Session HIGH POINT, N.C. --(BUSINESS WIRE)--Oct. 16, 2018-- vTv Therapeutics Inc.
View HTML
Toggle Summary vTv Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
HIGH POINT, N.C. --(BUSINESS WIRE)--Aug. 30, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced it will be featured as a presenting
View HTML
Toggle Summary vTv Therapeutics Announces Second Quarter 2018 Results and Update
HIGH POINT, N.C. --(BUSINESS WIRE)--Aug. 3, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter that ended June 30, 2018 , and provided an update on recent achievements and upcoming events. “Since our announcement regarding the topline results from
View HTML
Toggle Summary vTv Therapeutics to Present a Poster at the American Diabetes Association’s 78th Scientific Sessions
HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 22, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease, diabetes and other therapeutic areas, today announced that
View HTML
Toggle Summary vTv Therapeutics to Present a Poster at the American Diabetes Association’s 78th Scientific Sessions
HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 22, 2018-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease, diabetes and other therapeutic areas, today announced that
View HTML
Toggle Summary vTv Therapeutics Announces Topline Results from Part B of Phase 3 STEADFAST Study
HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 12, 2018-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that results from Part B of the Company’s STEADFAST Study of the investigational medication azeliragon in people with mild Alzheimer’s disease did not meet co-primary efficacy endpoints.
View HTML